The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 30, 2022

Filed:

Dec. 12, 2019
Applicants:

Institut National DE LA Santé ET DE LA Recherche Médicale, Paris, FR;

Centre National DE LA Recherche Scientifique—cnrs, Paris, FR;

Inventors:

Thierry Leveillard, Maisons-Alfort, FR;

Jose-Alain Sahel, Paris, FR;

Celine Jaillard, Antony, FR;

Olivier Poch, Strasbourg, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/18 (2006.01); C07K 14/475 (2006.01); C07K 14/48 (2006.01); C07K 14/47 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 48/00 (2006.01); G01N 33/68 (2006.01); C07K 14/00 (2006.01); C07K 14/435 (2006.01); A61K 38/17 (2006.01); A61K 38/44 (2006.01); C12Q 1/6883 (2018.01);
U.S. Cl.
CPC ...
G01N 33/6896 (2013.01); A61K 38/1709 (2013.01); C07K 14/00 (2013.01); C07K 14/435 (2013.01); A61K 38/44 (2013.01); C12Q 1/6883 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/2835 (2013.01);
Abstract

The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform inof the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.


Find Patent Forward Citations

Loading…